Sunlight GLP-1 2026: FDA's Decision on Compounded Semaglutide

Key Takeaways

• February 21, 2025: FDA declared semaglutide injection shortage resolved (Ozempic/Wegovy).
• Copy compounding discretion ended April 22, 2025 (503A) and May 22, 2025 (503B).
• April 30, 2026: FDA proposed excluding semaglutide from the 503B Bulks List for lack of clinical need.
• February 6, 2026 enforcement statement targets mass-marketed unapproved GLP-1 products and ads.

What is the core 2026 decision on compounded semaglutide?

By mid-2026, FDA’s public position is that routine compounding of essentially identical semaglutide copies is not authorized under shortage exceptions, and outsourcing facilities lack a 503B Bulks List pathway under the April 30 proposal.

Patients needing therapy should use FDA-approved products when available. Localized pharmacy stock issues do not automatically reopen national shortage compounding.

Which primary documents lock the timeline?

Key agency records include:

• Declaratory order (Feb 21, 2025) resolving the semaglutide injection shortage
• Compounder policy page with 503A/503B wind-down dates
• April 30, 2026 503B Bulks exclusion proposal

How does the April 2026 503B proposal change the math?

Even after shortage resolution, some compounders looked to bulk API strategies. FDA’s proposal finds no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk and invites comments through late June 2026 via the Federal Register docket summarized on GovInfo as FR Doc. 2026-08552.

If finalized, the bulk gateway for 503B copies of these APIs would remain closed absent a future shortage listing.

What enforcement themes defined early 2026?

FDA’s February 6, 2026 announcement said the agency intends to restrict GLP-1 APIs intended for non-approved compounded drugs that are mass-marketed as alternatives to approved therapies. Misleading “generic” or “same active ingredient” claims are in scope.

Warning letters through 2025 already challenged websites promoting compounded semaglutide and tirzepatide with comparative claims.

Practical guidance for clinics and telehealth

Stop advertising compounded semaglutide as interchangeable with Wegovy or Ozempic. If any 503A compounding is contemplated, document a patient-specific clinical difference that avoids the “essentially a copy” prohibition and meet all other statutory conditions.

Supply planning should assume branded or authorized generic channels—not compounding volume—as the base case for 2026.

What remains unsettled?

Final 503B Bulks List determinations depend on comment review. State boards may impose additional limits. Litigation over shortage decisions previously sought injunctions but did not restore open-ended mass compounding in FDA’s later 2026 guidance posture.

“Sunlight” narratives that promise a 2026 reopening of mass compounded semaglutide lack support in the cited FDA records.

Related NovaPharma coverage

• FDA's Permanent Ban on Compounded GLP-1s
• FDA Proposes Regulations on Weight-Loss Drug Compounding
• Semaglutide drug profile

Frequently Asked Questions

Primary Sources

1. FDA: Semaglutide shortage declaratory order (Feb 21, 2025)
2. FDA: April 30, 2026 503B Bulks exclusion proposal
3. FDA: Compounder policies as GLP-1 supply stabilizes